biote (BTMD) AI Stock Analysis

• Market Cap: $158.54M
• Dividend Yield: N/A
• Average Volume (3M): 121.14K
• Price to Earnings (P/E): 7.0
• Beta (1Y): 1.07
• Revenue Growth: 6.44%
• EPS Growth: 322.20%
• Country: US
• Employees: 217
• Sector: Healthcare
• Sector Strength: 46
• Industry: Medical - Care Facilities
• EPS (TTM): 0.37
• Shares Outstanding: 33,073,277
• 10 Day Avg. Volume: 111,465
• 30 Day Avg. Volume: 121,140
• PEG Ratio: -0.19
• Price to Book (P/B): -0.68
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.73
• Enterprise Value/Market Cap: 0.45
• Enterprise Value/Revenue: 0.09
• Enterprise Value/Gross Profit: 0.50
• Enterprise Value/Ebitda: 0.98
• 1Y Price Target: $6.00
• Price Target Upside: 40.19% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

• Rating: 67 Neutral
• Price Target: $4.50 ▲(5.14%Upside)

BTMD has a solid revenue growth trajectory and strong cash flow generation, but negative equity and balance sheet risks weigh heavily. The stock is undervalued based on P/E ratio and shows some technical bullish signals. Corporate events and earnings call outcomes are mixed but indicate strategic realignments that may benefit future performance.

Positive Factors

Business Growth

The supplements business was a bright spot, growing by 25% due to moving to Amazon.

Consumer Loyalty

The market opportunity remains attractive and the end consumer remains loyal to BTMD's products even in a choppy macro backdrop.

Organizational Strategy

Management announced an organizational restructuring to support new clinic growth by realigning resources and increasing sales representatives by 25% without increasing headcount.

Negative Factors

Clinic Growth

New clinic growth began to soften as BTMD rolled out the proprietary clinical decision support software.

Revenue Impact

Average selling price declined modestly, affecting Procedure revenue.

Software Transition Challenges

Ongoing software transition issues will linger, and it will likely take 2+ quarters for trends to start to show improvement.

biote Business Overview & Revenue Model

Company Description

biote Corp. operates in medical practice-building business within the hormone optimization space. The company offers a platform for Biote-certified practitioners to optimize imbalances in their patient's hormone, vitamin, and mineral levels, as well as prescribe bioidentical hormone therapies and recommend dietary supplements. It also sells Biote-branded dietary supplements; and sterile pellet insertion kits for men and women. The company was founded in 2011 and is headquartered in Irvine, Texas.

How the Company Makes Money

Biote makes money through a multi-faceted revenue model that includes the sale of bioidentical hormone replacement products to healthcare practitioners who are certified through Biote's extensive training programs. Additionally, the company generates income by offering certification and ongoing training programs for practitioners, thereby ensuring they are equipped to provide the best care using Biote's products. Key partnerships with healthcare providers and clinics further enhance Biote's market reach, contributing significantly to its earnings. The combination of product sales, educational services, and strategic partnerships forms the backbone of Biote's revenue streams.

biote Financial Statement Overview

Summary

The company shows strong revenue growth and profitability improvement with a healthy gross profit margin. However, the negative equity poses a significant risk to financial stability, necessitating stronger financial restructuring for long-term sustainability.

Income Statement

The company shows a positive trend in revenue growth, with a notable increase in total revenue from previous years. Gross profit margin is healthy at approximately 71.2% TTM. Net profit margin has improved significantly to 10.9% TTM from lower levels in previous years, indicating better cost management and operational efficiency. However, EBIT and EBITDA margins are moderate at 15.5% and 9.1% TTM, respectively, suggesting room for improvement in operational leverage.

Balance Sheet

The balance sheet is concerning with a negative stockholders' equity indicating that liabilities exceed assets. The debt-to-equity ratio cannot be calculated due to negative equity, highlighting financial risk. Despite these challenges, the company has managed to increase its cash reserves, which could provide some liquidity buffer. The equity ratio remains negative due to the negative equity, reflecting a need for stronger financial restructuring.

Cash Flow

Cash flow generation is strong, with positive free cash flow and operating cash flow. The free cash flow to net income ratio indicates efficient conversion of earnings into cash. The company improved its operating cash flow to net income ratio, suggesting effective cash management. The free cash flow growth rate is substantial, reflecting improved cash generation capabilities. However, investing cash flow remains negative, which could impact future growth initiatives.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	199.38M	197.19M	185.36M	164.96M	139.40M	116.57M
Gross Profit	142.01M	139.06M	127.48M	110.38M	90.58M	71.64M
EBITDA	18.17M	15.59M	9.23M	9.24M	35.98M	32.91M
Net Income	21.80M	3.16M	3.32M	1.32M	32.62M	29.16M
Balance Sheet
Total Assets	123.38M	122.37M	155.29M	111.64M	54.33M	32.59M
Cash, Cash Equivalents and Short-Term Investments	41.70M	39.34M	89.00M	79.23M	26.77M	17.21M
Total Debt	9.54M	110.86M	114.87M	120.43M	37.34M	42.35M
Total Liabilities	208.21M	224.57M	191.84M	169.92M	50.20M	49.66M
Stockholders Equity	-84.83M	-105.93M	-29.40M	-44.46M	4.13M	-17.07M
Cash Flow
Free Cash Flow	36.81M	38.81M	24.17M	-10.99M	29.91M	25.03M
Operating Cash Flow	44.34M	45.24M	26.88M	-9.16M	33.72M	26.43M
Investing Cash Flow	-8.47M	-18.80M	-2.71M	-1.84M	-3.81M	-1.39M
Financing Cash Flow	-72.93M	-76.08M	-14.38M	63.46M	-20.34M	-18.32M

biote Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.28
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BTMD, the sentiment is Positive. The current price of 4.28 is above the 20-day moving average (MA) of 3.86, above the 50-day MA of 3.73, and below the 200-day MA of 4.86, indicating a neutral trend. The MACD of 0.11 indicates Negative momentum. The RSI at 63.13 is Neutral, neither overbought nor oversold. The STOCH value of 78.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BTMD.

biote Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BTMD	67 Neutral	$158.54M	7.00	-7.92%	―	6.44%	322.20%
AUNA	58 Neutral	$469.24M	11.06	9.93%	―	6.97%	―
AIRS	55 Neutral	$305.83M	―	-21.30%	―	-12.96%	-1199.26%
DCGO	52 Neutral	$160.55M	12.68	-0.21%	―	-26.00%	-103.18%
Sector *	51 Neutral	$7.41B	0.36	-61.88%	2.34%	16.99%	1.69%
CMPS	47 Neutral	$256.26M	―	-60.67%	―	―	3.88%
TOI	46 Neutral	$197.61M	―	-227.77%	―	17.64%	13.86%

biote Corporate Events

Biote Appoints Richard Barrera to Board of Directors

On June 5, 2025, Biote Corp. appointed Richard R. Barrera to its Board of Directors, filling the vacancy left by Steven J. Heyer’s resignation. Barrera, an experienced finance professional and founder of Roystone Capital, is expected to bring valuable insights to Biote’s growth strategy, aligning with the company’s long-term value creation goals. His appointment is seen as a strategic move to strengthen Biote’s board with financial expertise, potentially enhancing its market positioning and stakeholder confidence.

The most recent analyst rating on (BTMD) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on biote stock, see the BTMD Stock Forecast page.

Biote Director Steven J. Heyer Resigns

On June 2, 2025, Steven J. Heyer resigned from the Board of Directors of biote Corp. with immediate effect. His resignation was not due to any disagreements with the company’s operations or policies, and the Board has yet to appoint a replacement.

The most recent analyst rating on (BTMD) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on biote stock, see the BTMD Stock Forecast page.

Biote Corp. Elects New Directors at Annual Meeting

On May 13, 2025, biote Corp. held its annual meeting of stockholders where key decisions were made regarding the company’s leadership and financial oversight. Stockholders elected Marc D. Beer and Bret Christensen as Class III directors to serve until 2028, and ratified Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (BTMD) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on biote stock, see the BTMD Stock Forecast page.

Biote Announces Organizational Restructuring for Growth

On May 1, 2025, Biote’s Board of Directors approved an organizational restructuring plan to enhance operational and financial performance, which was completed by May 5, 2025. The restructuring aims to prioritize new clinic growth and improve accountability, involving a workforce reduction of 16 employees and incurring pre-tax restructuring charges of $0.6 to $0.8 million. Biote reported strong financial results for the first quarter of 2025, with a revenue increase of 4.7% year-over-year, driven by a significant rise in dietary supplements revenue. The company maintains its financial outlook for 2025, expecting continued growth in procedure and dietary supplements revenue.

Biote Reduces Marc Beer’s Salary Amid Transition

On April 1, 2025, Marc Beer, Executive Chairman of biote Corp., transitioned from full-time to part-time employment as part of the Board of Directors’ leadership transition plan. Consequently, on April 22, 2025, the Compensation Committee reduced his annual base salary from $490,000 to $196,000, effective retroactively from the transition date, with an expectation for him to become Non-Executive Chairman by the end of the third quarter of 2025.